Permanent injunction covers sale, use, and export of products and components.
Innogenetics reported that a U.S. court entered a permanent injunction against Abbott Laboratories, prohibiting the company from selling or using products, including components, that infringe on Innogenetics’ patented Hepatitis C Virus genotyping technology. The injunction also prevents Abbott from exporting components of the infringing products to foreign countries.
In September 2006 a jury unanimously found that Abbott had willfully infringed Innogenetics’ U.S. patent 5,846,704 and awarded the company $7 million in damages.
The U.S. District Court for the Western District of Wisconsin made the ruling at the close of an evidentiary hearing to determine the potential public impact of a permanent injunction against Abbott. Last week, the court found that Innogenetics suffered irreparable harm from Abbott’s infringement.
